46-fda-to-store

This package is the complete “FDA-to-Store” bundle — everything needed to understand three original disease-mechanism discoveries, the real United States regulatory road each one must travel to become a medicine, and the one lawful alternative (DSHEA dietary supplement) available if the drug road is never completed. It brings together three full research deliverables, five companion educational documents, reference charts, patent drawings, formulation charts, source code, and raw discovery data under a single product.

The three discoveries were produced by Christopher Gabriel Brown’s Alchemy Data V2 system — a computational database of elemental combinations, transformation pathways, synthesis methods, and probability scores drawn from pharmaceutical databases and drug reference indices. The system scanned 24.4 million+ element combinations against 257,500 synthesis methods, then cross-referenced every finding against published peer-reviewed literature indexed in PubMed.

What makes this package unusual is its honesty: every report includes corrected V3 editions that openly state where previous versions contained overstatements, where evidence is strong, where it is weak or negative, and where the word “cure” should not be used. The package is candid that holding intellectual property is the starting line, not the finish.

The deliverable contains three full sub-projects plus five companion Open Research documents, totalling approximately 99+ files across documentation, data, source code, images, patent filings, and reference charts.

Safety-informed 30-day formula parameters: zinc capped at 30 mg/day (below the 40 mg tolerable upper limit), copper 2 mg to prevent zinc-induced copper depletion, zinc and magnesium dosed separately (AM/PM), iron excluded (pro-oxidant risk to beta cells).

The V3 corrected report is notable for its scientific honesty. V1 (January 2026) contained fundamentally inverted claims — stating that zinc prevents amyloid aggregation when published science (Bush et al. 1994, Science, 1,900+ citations) shows zinc promotes it. V3 corrects all such errors.

The discipline that makes this package credible: the Alzheimer’s formula deliberately excludes copper, iron, zinc, and aluminium supplementation. The package is candid that the most defensible directions are the non-metal ones: glutathione restoration (NAC/cysteine) and magnesium correction.

The Parkinson’s package is the strongest of the three — the only one whose lead direction already has human PD trial data, and the only one with a genuinely novel compound class.

L-DOPA interaction warning: Metal ions (iron, zinc, copper) chelate levodopa in the GI tract, reducing absorption by 30–70%. PD patients on levodopa/carbidopa must separate metal-containing supplements by at least 2 hours.

The package includes a comprehensive plain-English guide to every real step in the US drug-approval process, governed by the Federal Food, Drug, and Cosmetic Act and enforced by the FDA’s CDER (or CBER for biologics):

Optional fast lanes: Fast Track (rolling submission), Breakthrough Therapy (intensive FDA guidance), Accelerated Approval (surrogate endpoint, confirmatory trials required), Priority Review (6-month goal).

Typical cost: ~$700 million to $2.6 billion. Typical timeline: 10–15 years. Success rate from first human dose: approximately 1 in 10.

Each per-disease companion document explains the one lawful route that needs no FDA pre-approval — a dietary supplement under the Dietary Supplement Health and Education Act of 1994 (DSHEA). The trade: a supplement may never claim to diagnose, treat, cure, or prevent a disease. The package details:

All three applications cover: compound compositions, pharmaceutical formulations, methods of treatment, methods of synthesis (pH 7–8, 60–80°C), combination therapy with existing approved drugs, and use for manufacture of medicament. Amino acid specificity claims cover glycine, alanine, serine, threonine, cysteine, methionine, aspartic acid, glutamic acid, lysine, arginine, histidine, and combinations thereof.

This is NOT medical advice. These are computational research findings, not clinically validated treatments. The compounds described have not been synthesised for medical use, not been tested in cell cultures, animals, or humans for the indicated conditions (except where outside researchers’ published work is cited), not been reviewed or approved by any regulatory agency, and not been validated through clinical trials. Do not attempt to self-treat any medical condition based on this research. Consult a licensed physician. Many elements discussed (zinc, copper, iron) can be toxic at improper doses. This product is not affiliated with or endorsed by the FDA, USPTO, or any pharmaceutical company. The discoveries described are supplement-grade research, not FDA-approved drugs. Dietary-supplement rules (DSHEA, NDI, 21 CFR 101/111) and the NAC enforcement-discretion policy change over time — confirm current requirements with the FDA and qualified counsel before manufacturing or labelling anything. Confirm anything regulatory against current FDA guidance at fda.gov.

This package ships on a single Blu-ray disc, posted to the delivery address on your order. The archive on the disc is AES-256 encrypted; the passphrase is sent separately, by email, once the disc is despatched — so the disc alone is of no use to anyone who intercepts it.

Discs are despatched by tracked, signed-for post. Allow 5 business days for mastering and verification before despatch.

© 2026 Christopher Gabriel Brown